Journal Reviews

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

12 October 2022 | | Urologic Oncology | #BladderCancer, #blcsm, cytosine arabinoside, intravesical therapy, mitomycin C, non-muscle-invasive bladder cancer, randomised trial, #uroonc, urinary pH

Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...